Remote Ischemic Conditioning Using the autoRIC (SHIELD)
Primary Purpose
Ischemia-Reperfusion Injury
Status
Unknown status
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
autoRIC
autoRIC Sham
Sponsored by
About this trial
This is an interventional prevention trial for Ischemia-Reperfusion Injury focused on measuring remote ischemic conditioning (RIC), percutaneous coronary intervention, PCI, cardiac troponin I, cardiac catheterization, myocardial injury, myocardial necrosis, autoRIC, Ischemia-Reperfusion Injury (IRI), Automated Remote Ischemic Conditioning
Eligibility Criteria
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject is scheduled for elective PCI, or unscheduled but non-emergent PCI, or diagnostic catheterization with PCI if indicated. For non-elective cases, there must be at least two troponin levels within the upper limit of normal (ULN), at least 6 hours apart prior to the index procedure
- Subject is willing and capable of providing written informed consent
- If the subject is a woman of childbearing potential, she must have had a negative pregnancy test within 24 hours of the study procedure
Exclusion Criteria:
- Subject requires emergency PCI (i.e., PCI for evolving or ongoing STEMI/NSTEMI)
- Subject has an elevated troponin level (cTnI or T) > ULN at baseline, based on lab results obtained from the treating institution
- Subject is scheduled to undergo PCI with the use of Propofol
- Subject has a recent history of drug treatment with potassium channel activators (e.g., Nicorandil) or potassium channel blockers (e.g., sulfonylureas) during the last 7 days prior to baseline
- Subject had STEMI during the last 4 weeks prior to baseline. (Note: NSTEMI in the last 4 weeks prior to baseline is allowed if the baseline troponin is ≤ ULN.)
- Underwent a CABG in the last 4 weeks prior to baseline
- Had a PCI within the last 7 days prior to baseline
- Subject has a life expectancy < 6 months
- Subject has NYHA Class IV or decompensated heart failure
- Subject has peripheral vascular disease requiring intervention during the index hospitalization or within 4 weeks post-procedure
- Subject has either serum creatinine >2 times the age-appropriate upper limit of normal, a glomerular filtration rate (GFR) of < 30 mL/min/1.73m2 or requires dialysis
- Subject has systolic blood pressure > 200 mmHg
- Subject is currently being treated with systemic oral or I.V. steroids
- Subject has a known bleeding disorder or known abnormality of blood flow to the limb to be treated
- Subject has peripheral nerve injury, abnormal nerve supply, peripheral neuropathy or pre-existing traumatic injury to the limb to be treated
- Subject is scheduled for a PCI procedure to treat a known Chronic Total Occlusion (CTO) lesion
- Subject is currently participating in or is planning to participate in another investigational drug or device trial, prior to the 30-day follow-up visit. (Note: Observational studies or post-approval studies/ registries, are allowed.)
- Planned (staged) post-index procedure intervention within 30 days (i.e., PCI of non-target lesions in any vessel or CABG). (Note: Planned revascularization (PCI or bypass) of a non-target lesion >30 days following the index procedure is allowed.)
- Any cardiac surgical procedure planned within 30 days post-enrollment
Sites / Locations
- University of Alabama at BirminghamRecruiting
- Danbury HospitalRecruiting
- University of Florida Health JacksonvilleRecruiting
- Iowa Heart CenterRecruiting
- Henry Ford HospitalRecruiting
- Henry Ford West Bloomfield HospitalRecruiting
- Saint Luke's Hospital of Kansas CityRecruiting
- Southside HospitalRecruiting
- North Shore University HospitalRecruiting
- Mount Sinai HospitalRecruiting
- Lenox Hill HospitalRecruiting
- Staten Island University HospitalRecruiting
- Novant Health Heart and Vascular InstituteRecruiting
- NC Heart and Vascular ResearchRecruiting
- William Osler Health SystemRecruiting
- St. Michael's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
autoRIC
autoRIC Sham
Arm Description
The autoRIC device will be used on subjects randomized to the treatment group.
The autoRIC Sham device will be used on subjects randomized to the control group.
Outcomes
Primary Outcome Measures
(Primary Effectiveness) Attenuation of myocardial injury assessed by Cardiac Troponin I levels (cTnI)
The proportion of subjects with cTnI levels above the 99th percentile Upper Reference Limit (URL) (0.04 ng/mL) 12-24 hours post-PCI.
(Primary Safety) Major Adverse Cardiac Events (MACE)
The proportion of subjects with major adverse cardiac events (MACE) within 30 days. MACE is defined as: death, stroke, myocardial infarction or the need for target vessel revascularization.
Secondary Outcome Measures
Type 4a Myocardial Infarction (MI)
The proportion of subjects with a Type 4a MI within 12-24 hours post- PCI.
Contrast-Induced Acute Kidney Injury (CI-AKI)
The proportion of subjects with CI-AKI defined as > 25% or 0.5 mg/dl increase in serum creatinine above baseline within 12-24 hours post-PCI.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03318575
Brief Title
Remote Ischemic Conditioning Using the autoRIC
Acronym
SHIELD
Official Title
Safety and Effectiveness of Remote Ischemic Conditioning With the autoRIC Prior to Elective Percutaneous Coronary Intervention (PCI) Study
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Unknown status
Study Start Date
January 30, 2018 (Actual)
Primary Completion Date
April 2019 (Anticipated)
Study Completion Date
April 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CellAegis US, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to evaluate the hypothesis that patients receiving remote ischemic conditioning using the autoRIC device show statistically significant reduction in the prevalence of ischemia-reperfusion injury to the myocardium as compared to patients in the autoRIC Sham device arm (within 12-24 hours post non-emergent PCI with stent implantation).
Detailed Description
This is a multi-center, randomized, controlled single-blind clinical trial to evaluate the safety and effectiveness of the autoRIC device to attenuate myocardial injury as measured by cardiac Troponin I (cTnI) levels in patients undergoing PCI with stent implantation.
Eligible patients that are scheduled for an elective PCI, or unscheduled/non-emergent PCI, or patients scheduled for a diagnostic catheterization procedure with orders of "treat as indicated" will be enrolled in the study. Patients will undergo remote ischemic conditioning with the autoRIC device or the control procedure with the autoRIC Sham device completed ≤ 1 hour prior to balloon or stent inflation. Subjects will have measurements of cTnI levels at baseline and 4-8 and 12-24 hours post completion of the PCI procedure. Adverse events will be recorded through study exit for all patients. Patients will be exited from the study after completion of their 30-day post-procedure telephone follow-up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemia-Reperfusion Injury
Keywords
remote ischemic conditioning (RIC), percutaneous coronary intervention, PCI, cardiac troponin I, cardiac catheterization, myocardial injury, myocardial necrosis, autoRIC, Ischemia-Reperfusion Injury (IRI), Automated Remote Ischemic Conditioning
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
autoRIC
Arm Type
Experimental
Arm Description
The autoRIC device will be used on subjects randomized to the treatment group.
Arm Title
autoRIC Sham
Arm Type
Sham Comparator
Arm Description
The autoRIC Sham device will be used on subjects randomized to the control group.
Intervention Type
Device
Intervention Name(s)
autoRIC
Intervention Description
Automated Remote Ischemic Conditioning
Intervention Type
Device
Intervention Name(s)
autoRIC Sham
Intervention Description
Automated Remote Ischemic Conditioning Sham
Primary Outcome Measure Information:
Title
(Primary Effectiveness) Attenuation of myocardial injury assessed by Cardiac Troponin I levels (cTnI)
Description
The proportion of subjects with cTnI levels above the 99th percentile Upper Reference Limit (URL) (0.04 ng/mL) 12-24 hours post-PCI.
Time Frame
12-24 hours
Title
(Primary Safety) Major Adverse Cardiac Events (MACE)
Description
The proportion of subjects with major adverse cardiac events (MACE) within 30 days. MACE is defined as: death, stroke, myocardial infarction or the need for target vessel revascularization.
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Type 4a Myocardial Infarction (MI)
Description
The proportion of subjects with a Type 4a MI within 12-24 hours post- PCI.
Time Frame
12-24 hours
Title
Contrast-Induced Acute Kidney Injury (CI-AKI)
Description
The proportion of subjects with CI-AKI defined as > 25% or 0.5 mg/dl increase in serum creatinine above baseline within 12-24 hours post-PCI.
Time Frame
12-24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is ≥ 18 years of age
Subject is scheduled for elective PCI, or unscheduled but non-emergent PCI, or diagnostic catheterization with PCI if indicated. For non-elective cases, there must be at least two troponin levels within the upper limit of normal (ULN), at least 6 hours apart prior to the index procedure
Subject is willing and capable of providing written informed consent
If the subject is a woman of childbearing potential, she must have had a negative pregnancy test within 24 hours of the study procedure
Exclusion Criteria:
Subject requires emergency PCI (i.e., PCI for evolving or ongoing STEMI/NSTEMI)
Subject has an elevated troponin level (cTnI or T) > ULN at baseline, based on lab results obtained from the treating institution
Subject is scheduled to undergo PCI with the use of Propofol
Subject has a recent history of drug treatment with potassium channel activators (e.g., Nicorandil) or potassium channel blockers (e.g., sulfonylureas) during the last 7 days prior to baseline
Subject had STEMI during the last 4 weeks prior to baseline. (Note: NSTEMI in the last 4 weeks prior to baseline is allowed if the baseline troponin is ≤ ULN.)
Underwent a CABG in the last 4 weeks prior to baseline
Had a PCI within the last 7 days prior to baseline
Subject has a life expectancy < 6 months
Subject has NYHA Class IV or decompensated heart failure
Subject has peripheral vascular disease requiring intervention during the index hospitalization or within 4 weeks post-procedure
Subject has either serum creatinine >2 times the age-appropriate upper limit of normal, a glomerular filtration rate (GFR) of < 30 mL/min/1.73m2 or requires dialysis
Subject has systolic blood pressure > 200 mmHg
Subject is currently being treated with systemic oral or I.V. steroids
Subject has a known bleeding disorder or known abnormality of blood flow to the limb to be treated
Subject has peripheral nerve injury, abnormal nerve supply, peripheral neuropathy or pre-existing traumatic injury to the limb to be treated
Subject is scheduled for a PCI procedure to treat a known Chronic Total Occlusion (CTO) lesion
Subject is currently participating in or is planning to participate in another investigational drug or device trial, prior to the 30-day follow-up visit. (Note: Observational studies or post-approval studies/ registries, are allowed.)
Planned (staged) post-index procedure intervention within 30 days (i.e., PCI of non-target lesions in any vessel or CABG). (Note: Planned revascularization (PCI or bypass) of a non-target lesion >30 days following the index procedure is allowed.)
Any cardiac surgical procedure planned within 30 days post-enrollment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vera Belaoussoff
Phone
647-722-9601
Ext
105
Email
vbelaoussoff@cellaegisdevices.com
First Name & Middle Initial & Last Name or Official Title & Degree
Brad Solberg
Phone
408-400-0856
Email
brad@experiengroup.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roxana Mehran, MD
Organizational Affiliation
Cardiovascular Medicine Associates
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick Frazier, RN
Phone
205-934-5774
Email
CCTU@uabmc.edu
First Name & Middle Initial & Last Name & Degree
Massoud Leesar, MD
Facility Name
Danbury Hospital
City
Danbury
State/Province
Connecticut
ZIP/Postal Code
06810
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monica Tawadros, MPH
Phone
203-739-7134
Email
Monica.Tawadros@wchn.org
First Name & Middle Initial & Last Name & Degree
Hal Wasserman, MD
Facility Name
University of Florida Health Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32209
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emily Green, BSN, RN
Phone
904-244-2794
Email
emily.green@jax.ufl.edu
First Name & Middle Initial & Last Name & Degree
Andres Pineda Maldonado, MD
Facility Name
Iowa Heart Center
City
Des Moines
State/Province
Iowa
ZIP/Postal Code
50314
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kassandra Seitz, BSN, RN
Phone
515-235-5114
Email
kseitz@iowaheart.com
First Name & Middle Initial & Last Name & Degree
Magdi Ghali, MD
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Margaret Fox, RN, BSN
Phone
313-916-1879
Email
mfox2@hfhs.org
First Name & Middle Initial & Last Name & Degree
Gerald Koenig, MD, PhD
Facility Name
Henry Ford West Bloomfield Hospital
City
West Bloomfield
State/Province
Michigan
ZIP/Postal Code
48322
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mishel Tabaku
Phone
248-325-0737
Email
Mtabaku1@hfhs.org
First Name & Middle Initial & Last Name & Degree
Gerald Koenig, MD, PhD
Facility Name
Saint Luke's Hospital of Kansas City
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64111
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lisa Lacy, RCIS
Phone
816-932-7528
Email
lnewhouse@saint-lukes.org
First Name & Middle Initial & Last Name & Degree
John Saxon, MD
Facility Name
Southside Hospital
City
Bay Shore
State/Province
New York
ZIP/Postal Code
11706
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Shannon, RN, BSN
Phone
631-968-3016
Email
bshannon@northwell.edu
First Name & Middle Initial & Last Name & Degree
Cindy Grines, MD
Facility Name
North Shore University Hospital
City
Manhasset
State/Province
New York
ZIP/Postal Code
11030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruby Garzon, RN, MSN
Phone
516-562-4168
Email
rgrazon@northwell.edu
First Name & Middle Initial & Last Name & Degree
Cindy Grines, MD
Facility Name
Mount Sinai Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Saint Vrestil, BA
Phone
212-241-9687
Email
nicole.saintvrestil@mountsinai.org
First Name & Middle Initial & Last Name & Degree
Joseph Sweeney, MD
Facility Name
Lenox Hill Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10075
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Priscilla Chu, BA
Phone
212-434-3362
Email
Pchu3@northwell.edu
First Name & Middle Initial & Last Name & Degree
Cindy Grines, MD
Facility Name
Staten Island University Hospital
City
Staten Island
State/Province
New York
ZIP/Postal Code
10305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richie Dima, MD
Phone
718-226-1489
Email
rdima@northwell.edu
First Name & Middle Initial & Last Name & Degree
Cindy Grines, MD
Facility Name
Novant Health Heart and Vascular Institute
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pailing Richards, RN, BSN
Phone
704-264-1400
Email
pcrichards@novanthealth.org
First Name & Middle Initial & Last Name & Degree
Amjad Almahameed, MD
Facility Name
NC Heart and Vascular Research
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James R Pierre-Louis, MD, CRS
Phone
919-784-7695
Email
james.pierre-louis@unchealth.unc.edu
First Name & Middle Initial & Last Name & Degree
Mohit Pasi, MD
Facility Name
William Osler Health System
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6R 3J7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Kemp, BS
Phone
905-494-2120
Ext
58666
Email
James.kemp@williamoslerhs.ca
First Name & Middle Initial & Last Name & Degree
Shy Amlani, MD
Facility Name
St. Michael's Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B 1W8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ivana Kandic, MSc.
Phone
416-864-6060
Ext
6120
Email
kandici@smh.ca
First Name & Middle Initial & Last Name & Degree
Akshay Bagai, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Remote Ischemic Conditioning Using the autoRIC
We'll reach out to this number within 24 hrs